Skip to main content

Month: April 2025

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled “Gazing Through the Crystal Ball.” The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates. Register here For more information: https://www.clearmindmedicine.com/upcoming-events/gazing-through-the-crystal-ball Featured Speakers Include: Rick Doblin, PhD – Founder and...

Continue reading

Senti Bio Participates in a Virtual Investor KOL Connect Segment

Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio KOL Connect segment now available here SOUTH SAN FRANCISCO, Calif., April 21, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the release of a Virtual Investor KOL segment featuring Stephen Strickland, MD, MSCI, leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute (SCRI). As part of the segment, Kanya Rajangam, MD, PhD, President, Head of R&D...

Continue reading

Pretzelmaker® Rolls Out Free Pretzel Bites for National Pretzel Day

Pretzel Chain Bakes Up Limited-Time Offer for National Holiday with a Twist! LOS ANGELES, April 21, 2025 (GLOBE NEWSWIRE) — Pretzelmaker, owned by FAT Brands Inc. and innovator of Pretzel Bites, is celebrating National Pretzel Day this year by bringing back a fan-favorite deal, fresh out of the oven. On April 26, fans can enjoy a FREE order of Small Original Pretzel Bites, Salted or Unsalted, in-store at participating locations nationwide. For even more twists this year, Pretzelmaker is also throwing a “National Pretzel Day After Party” – guests who sign up for Pretzelmaker’s Rewards App by 11:59 p.m. April 26 will receive $5 off orders of $20 more starting April 27. This offer is valid for 14 days and can be redeemed in-store or online. “We’re excited to help our loyal fans save some dough this year with the return of our free...

Continue reading

AmpliTech Group Achieves REACH and RoHS Certification For Its 5G ORAN Low Power and Mid Power Radios, Reinforcing Commitment to Sustainability and Compliance

Meeting the rigorous regulatory standards required by international markets HAUPPAUGE, N.Y., April 21, 2025 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a leading designer, developer, and manufacturer of advanced signal processing components for satellite, public and private 5G, and other communications networks, including full 5G/6G system design and global distribution of integrated circuit assembly packages and lids, today is proud to announce that its 5G ORAN Low Power (LPRU) and Mid Power (MPRU) radios have successfully received REACH and RoHS certification. This significant achievement underscores the company’s ongoing commitment to environmental responsibility, product quality, and meeting the rigorous regulatory standards required by international markets. The REACH (Registration, Evaluation, Authorization,...

Continue reading

CompoSecure Integrates Arculus with MoneyGram: Becomes First Hardware Wallet to Provide Global Cash In/Cash Out Through Stellar

SOMERSET, N.J., April 21, 2025 (GLOBE NEWSWIRE) — CompoSecure, Inc. (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced the integration of its Arculus Cold Storage Wallet with MoneyGram Access™, which enables users to add and withdraw USDC in cash at participating MoneyGram locations. Arculus is the first hardware wallet to integrate with MoneyGram Access, enabling consumers to seamlessly convert physical cash into Circle USD Coin (USDC) on the Stellar blockchain and securely manage their digital dollars in the self-custody Arculus Cold Storage Wallet. Additionally, Arculus announced a grant from the Stellar Development Foundation (SDF), a non-profit organization supporting the development and growth of the Stellar network, to enable payments over traditional payment card...

Continue reading

Cloudastructure Secures Additional $3 Million Preferred Investment from Existing Institutional Investor

Palo Alto, CA, April 21, 2025 (GLOBE NEWSWIRE) — Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”), a leading cloud video surveillance provider of next-generation AI-powered solutions, today announced that it has secured an additional $3 million investment from an existing institutional investor through the issuance of Series 2 Convertible Preferred Stock. The additional capital is intended to support Cloudastructure’s ongoing expansion and advancement of its next-generation AI-powered security solutions. Under the terms of the agreement, Cloudastructure has issued 3,000 shares of Series 2 Convertible Preferred Stock at a purchase price of $1,000 per share. The Series 2 Preferred Stock carries a 9.5% annual preferred return and is convertible into shares of the Company’s Class A common...

Continue reading

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis. Overall, 133 patients were randomized and treated in the Phase II stage.   Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, “We are pleased to have completed the recruitment of patients in the Phase II stage of this trial, which follows the recently announced promising initial efficacy data from the Phase I stage. We therefore reiterate our timeline objective to obtain 3-month topline data by August 2025. We believe Allocetra™...

Continue reading

HCI Group Sets 2025 Annual Shareholders Meeting and Record Date

TAMPA, Fla., April 21, 2025 (GLOBE NEWSWIRE) — HCI Group, Inc. (NYSE: HCI) will hold its Annual Meeting of Shareholders on Tuesday, June 10, 2025, at 3:00 p.m. Eastern time in the 1st Floor Auditorium of HCI’s headquarters at 3802 Coconut Palm Drive, Tampa, Florida. Shareholders of record at the close of business on Monday, April 14, 2025, will be entitled to vote and attend the meeting. Items of business will include the following proposals:To elect Class B Directors To ratify the appointment of external auditors To approve, on an advisory basis, the compensation of the named executive officers To approve, on an advisory basis, of the frequency of votes on executive compensation.Shareholders will also consider such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof. About...

Continue reading

La Rosa Holdings Corp. Strategic Collaboration with Lofty to Drive Agent Productivity and Introduce New Recurring Revenue Stream

Celebration, FL, April 21, 2025 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech company,  today announced the successful implementation of its strategic collaboration with Lofty, an AI-powered productivity platform that aims to enhance agent performance and accelerates business growth. The platform supports La Rosa’s network of over 2,700 agents while advancing the Company’s ongoing national expansion strategy. Since its launch in November 2024, the Lofty platform has been adopted by over 500 La Rosa agents across the U.S., reflecting strong market demand, swift onboarding, and high user engagement. We believe that the platform’s low churn rate underscores its enduring value and strong reception among La Rosa agents. By automating routine tasks and streamlining workflows,...

Continue reading

Sofwave’s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC Region

Japan represents third largest non-surgical medical aesthetic market in the world SAN CLEMENTE, Calif., April 21, 2025 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has granted the Company approval to commercially market Sofwave’s SUPERB™ Technology. Market approval in Japan further extends Sofwave’s sales reach in the APAC territories, which now comprises major regional medical aesthetic device markets, including Japan, Australia, Taiwan, and South Korea. “We are delighted to broaden Sofwave’s commercial reach to Japan in 2025, which now enables us to sell additional devices across major markets in the APAC region,” said Sofwave’s Chief Executive...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.